VIRX

VIRACTA THERAPEUTICS INC by Viracta Therapeutics, Inc. (VIRX)

About VIRACTA THERAPEUTICS INC by Viracta Therapeutics, Inc. (VIRX)

Viracta Therapeutics, Inc. a clinical-stage, biomarker-directed precision oncology company focused on new medicines for the treatment of virus-associated malignancies. It develops antiviral agent valganciclovir as an oral combination therapy which is in a Phase 2 clinical trial for EBV-positive lymphomas. The company was founded on February 10, 1998 and is headquartered in Cardiff, CA.

Details

Daily high
$0.02
Daily low
$0.02
Price at open
$0.02
52 Week High
$0.68
52 Week Low
$0.01
Market cap
737,300
Dividend yield
0.00%
Volume
1,757
Avg. volume
115,499
P/E ratio
-.02

VIRACTA THERAPEUTICS INC by Viracta Therapeutics, Inc. News

Details

Daily high
$0.02
Daily low
$0.02
Price at open
$0.02
52 Week High
$0.68
52 Week Low
$0.01
Market cap
737,300
Dividend yield
0.00%
Volume
1,757
Avg. volume
115,499
P/E ratio
-.02